Concepedia

John A. Newitt

JA

Statistics

Publications

28

Citations

2.1K

H-Index

20

Active since

1986

Affiliations

Bristol-Myers Squibb (United States)(Current)

Bristol-Myers Squibb (Germany)

National Institute of Diabetes and Digestive and Kidney Diseases

National Institutes of Health

Bristol-Myers Squibb (Sweden)

John A. Newitt is an author at Bristol-Myers Squibb (United States) specializing in medicinal chemistry, drug discovery, and pharmacy.

ORCID

Publications per year

1986–2021

28

Publications

28

The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants

John S. Tokarski, John A. Newitt, Chieh Ying J. Chang et al. · Cancer Research · 2006 · 686 citations · Full text

, , +13

The E. coli Signal Recognition Particle Is Required for the Insertion of a Subset of Inner Membrane Proteins

Nancy D. Ulbrandt, John A. Newitt, Harris Bernstein · Cell · 1997 · 336 citations · Full text

, , +12

Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form

Micah T. Nelp, Patrick A. Kates, John T. Hunt et al. · Proceedings of the National Academy of Sciences · 2018 · 208 citations · Full text

, , +14

Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core

Prasanna Sivaprakasam, Xiaojun Han, Rita L. Civiello et al. · Bioorganic & Medicinal Chemistry Letters · 2015 · 116 citations · Full text

, , +16

Design, Synthesis, and Anti-inflammatory Properties of Orally Active 4-(Phenylamino)-pyrrolo[2,1-<i>f</i>][1,2,4]triazine p38α Mitogen-Activated Protein Kinase Inhibitors

John Hynes, Alaric J. Dyckman, Shuqun Lin et al. · Journal of Medicinal Chemistry · 2007 · 82 citations · Full text

, , +17

1–5 of 28